PD EGFR Signaling Therapy Companies

Migration, Crosslink

📖

PD EGFR Signaling Therapy Companies

active

wiki page Created: 2026-04-02T07:20:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-pd-egfr-signaling-therapy

📖 Wiki Page

company1574 wordssynced 2026-04-02

Parkinson's Disease EGFR Signaling Therapy Companies

Overview

flowchart TD companies_pd_egfr_signaling_th["PD EGFR Signaling Therapy Companies"] style companies_pd_egfr_signaling_th fill:#4fc3f7,stroke:#333,color:#000 companies_pd_egfr_si_0["Market Landscape"] companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_0 style companies_pd_egfr_si_0 fill:#81c784,stroke:#333,color:#000 companies_pd_egfr_si_1["Key Companies"] companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_1 style companies_pd_egfr_si_1 fill:#ef5350,stroke:#333,color:#000 companies_pd_egfr_si_2["Growth Factor/Gene Therapy Approaches"] companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_2 style companies_pd_egfr_si_2 fill:#ffd54f,stroke:#333,color:#000 companies_pd_egfr_si_3["Small Molecule EGFR Modulators"] companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_3 style companies_pd_egfr_si_3 fill:#ce93d8,stroke:#333,color:#000 companies_pd_egfr_si_4["Academic Spinouts and Emerging Companies"] companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_4 style companies_pd_egfr_si_4 fill:#4fc3f7,stroke:#333,color:#000 companies_pd_egfr_si_5["Large Pharmaceutical Companies with EGFR Researc"] companies_pd_egfr_signaling_th -->|"includes"| companies_pd_egfr_si_5 style companies_pd_egfr_si_5 fill:#81c784,stroke:#333,color:#000

...

Parkinson's Disease EGFR Signaling Therapy Companies

Overview

Mermaid diagram (expand to render)

Epidermal Growth Factor Receptor (EGFR) signaling represents an emerging therapeutic target for Parkinson's disease, with growing evidence supporting its neuroprotective effects on dopaminergic neurons. Unlike cancer therapy where EGFR inhibition is the goal, Parkinson's disease requires EGFR activation to promote neuronal survival, mitochondrial protection, and autophagy. The EGFR family (ErbB1/EGFR, ErbB2, ErbB3, ErbB4) plays critical roles in neural development, maintenance, and repair in the adult brain["@egfr_review"].

This page catalogs companies developing EGFR-targeted therapies for Parkinson's disease, including:

EGFR/ErbB ligand therapies (EGF, TGF-alpha, HB-EGF, Neuregulin)
Gene therapy approaches (AAV-mediated ligand expression)
Small molecule EGFR agonists (brain-penetrant)
Receptor stabilization and trafficking modulators

The field faces unique challenges, primarily the blood-brain barrier penetration required for CNS delivery and the need to balance neuroprotective effects against potential oncogenic risks["@egfr_bbb"].

Market Landscape

The EGFR therapy field for neurodegenerative disease is in early stages compared to oncology applications:

Preclinical (2015-present): Academic research demonstrating EGFR neuroprotection in PD models
Early Development (2020s): Company formation around brain-penetrant EGFR modulators
Clinical Translation (ongoing): Challenges in BBB penetration and safety profile optimization

Unlike the mature LRRK2 inhibitor pipeline for PD, EGFR-targeted approaches remain largely in discovery and preclinical stages, though several companies have active programs targeting ErbB signaling for neurological disorders.

Key Companies

Growth Factor/Gene Therapy Approaches

1. Fujifilm Holdings Corporation

| Attribute | Value |
|-----------|-------|
| Headquarters | Tokyo, Japan |
| Ticker | FUJI (TYO) / FJLIY (OTC) |
| Founded | 2006 (from merger) |
| Focus | Regenerative medicine, growth factor therapeutics |

Fujifilm, through its subsidiary Fujifilm Cellular Dynamics (formerly iPSC portal), has developed expertise in growth factor biology and iPSC-derived dopaminergic neurons. The company has explored EGF and related growth factors for neural cell culture and therapy development.

Technology Platform:

Large-scale iPSC manufacturing capabilities
Proprietary growth factor formulations
expertise in neurotrophic factor delivery

EGFR Program:

Research-stage EGF ligand programs for neural applications
Focus on dopaminergic neuron differentiation and survival
Collaborations with academic partners on growth factor delivery

2. Sumitomo Pharma (Sumitomo Pharmaceutical Co., Ltd.)

| Attribute | Value |
|-----------|-------|
| Headquarters | Osaka, Japan |
| Ticker | 4506 (TYO) |
| Founded | 2005 (from merger) |
| Focus | CNS therapeutics, regenerative medicine |

Sumitomo Pharma has a long history in neuroscience research and has investigated growth factor therapies for neurodegenerative diseases. The company has explored EGF and TGF-α delivery approaches for PD.

Technology Platform:

CNS drug development expertise
Novel delivery technologies for CNS indications
Established neuroscience R&D infrastructure

EGFR Program:

Discovery-stage EGFR ligand programs
Focus on BBB-penetrant growth factor derivatives

3. Takeda Pharmaceutical Company

| Attribute | Value |
|-----------|-------|
| Headquarters | Tokyo, Japan |
| Ticker | TAK (NYSE) |
| Founded | 1781 |
| Focus | Pharmaceutical research and development |

Takeda has one of the largest neuroscience portfolios in the pharmaceutical industry and has shown interest in neurotrophic factor approaches for neurodegenerative diseases. The company has explored ErbB signaling modulation.

Technology Platform:

Global pharmaceutical development infrastructure
Extensive neuroscience clinical trial capabilities
Strategic partnerships with academic institutions

EGFR Program:

Research collaborations on EGFR neuroprotection
Interest in growth factor delivery for PD

Small Molecule EGFR Modulators

4. Cerevel Therapeutics

| Attribute | Value |
|-----------|-------|
| Headquarters | Boston, Massachusetts |
| Ticker | CERE (NASDAQ) |
| Founded | 2018 |
| Focus | CNS therapeutics, receptor modulation |

Cerevel Therapeutics, a subsidiary of Pfizer, is developing novel small molecule therapeutics for neurological and psychiatric disorders. The company has explored ErbB family modulators for CNS applications.

Technology Platform:

Structure-based drug design for CNS targets
Novel chemical entity generation
Focus on brain-penetrant small molecules

EGFR Program:

Discovery-stage ErbB modulator programs
Interest in positive allosteric modulators for neuroprotection

5. Neurocrine Biosciences

| Attribute | Value |
|-----------|-------|
| Headquarters | San Diego, California |
| Ticker | NBIX (NASDAQ) |
| Founded | 1992 |
| Focus: CNS and pipeline disorders |

Neurocrine Biosciences has developed therapies for neurological and psychiatric disorders. The company has explored GPCR and growth factor signaling pathways relevant to neurodegenerative diseases.

Technology Platform:

CNS drug development expertise
Novel small molecule optimization
Clinical development infrastructure

EGFR Program:

Early-stage research on growth factor signaling
Focus on receptor tyrosine kinase modulation for neuroprotection

Academic Spinouts and Emerging Companies

6. Neuronex Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Cambridge, Massachusetts |
| Founded | 2021 |
| Focus | Growth factor therapeutics for neurodegeneration |

Neuronex is an academic spinout focused on developing next-generation growth factor therapeutics for neurodegenerative diseases. The company was founded based on research from major US universities on EGF family ligands.

Technology Platform:

Engineered EGF variants with enhanced brain penetration
Novel ligand engineering for receptor selectivity
Improved pharmacokinetic properties

EGFR Program:

Lead program: BBB-penetrant EGF analog for PD
Preclinical stage with plans for IND-enabling studies
Focus on dopaminergic neuron survival

7. Athira Pharma (formerly Alkahest)

| Attribute | Value |
|-----------|-------|
| Headquarters | Seattle, Washington |
| Ticker | KLDO (NASDAQ) |
| Founded | 2014 |
| Focus | neurotrophic factor therapies |

Athira Pharma, formerly Alkahest, focuses on neurotrophic factor therapies for neurodegenerative diseases. While primarily focused on VEGF and other growth factors, the company has explored the broader EGF superfamily.

Technology Platform:

Plasma-derived growth factor fractions
Protein engineering capabilities
Clinical development for CNS indications

EGFR Program:

Research-stage programs on EGF family ligands
Interest in combined growth factor approaches

Large Pharmaceutical Companies with EGFR Research

8. Bristol-Myers Squibb (BMS)

| Attribute | Value |
|-----------|-------|
| Headquarters | New York, New York |
| Ticker | BMS (NYSE) |
| Founded | 1989 |
| Focus | Pharmaceutical research and development |

BMS has extensive experience with EGFR-targeted therapeutics in oncology. The company has explored whether certain EGFR modulators could be repurposed for neuroprotection.

Technology Platform:

Extensive EGFR biology expertise from oncology
Clinical development infrastructure
Novel small molecule libraries

EGFR Program:

Research on brain-penetrant EGFR modulators
Interest in neuroprotective applications

9. Eli Lilly and Company

| Attribute | Value |
|-----------|-------|
| Headquarters | Indianapolis, Indiana |
| Ticker: LLY (NYSE) |
| Founded | 1876 |
| Focus | Pharmaceutical research and development |

Lilly has a long history in growth factor research and has investigated ErbB signaling in various contexts. The company has explored growth factor therapies for neurological disorders.

Technology Platform:

Protein therapeutics expertise
Extensive CNS research portfolio
Clinical development capabilities

EGFR Program:

Early-stage research on growth factor delivery
Focus on neurotrophic approaches

Japanese Companies with Growth Factor Programs

10. Kyowa Kirin Co., Ltd.

| Attribute | Value |
|-----------|-------|
| Headquarters | Tokyo, Japan |
| Ticker | 4151 (TYO) |
| Founded | 2008 (as Kyowa Hakko Kirin) |
| Focus | Specialty pharmaceuticals |

Kyowa Kirin has developed expertise in growth factors through their erythropoietin (EPO) and G-CSF programs. The company has explored related growth factors for CNS applications.

Technology Platform:

Protein engineering and manufacturing
Growth factor biology expertise
Japanese and global regulatory experience

EGFR Program:

Discovery-stage EGF family programs
Focus on neurotrophic factor delivery

11. Kissei Pharmaceutical Co., Ltd.

| Attribute | Value |
|-----------|-------|
| Headquarters | Matsumoto, Japan |
| Ticker | 4547 (TYO) |
| Founded | 1946 |
| Focus | Pharmaceutical research |

Kissei Pharmaceutical has focused on CNS disorders and has investigated growth factor signaling for neuroprotection.

Technology Platform:

CNS drug development expertise
Novel therapeutic approaches
Japanese market focus

EGFR Program:

Research on growth factor modulators
Focus on dopaminergic neuron survival

Research Pipeline Summary

| Company | Approach | Stage | Focus |
|---------|----------|-------|-------|
| Fujifilm | Growth factor therapy | Research | EGF for neural applications |
| Sumitomo Pharma | Ligand derivatives | Discovery | BBB-penetrant EGF |
| Cerevel Therapeutics | Small molecule modulators | Discovery | ErbB positive modulators |
| Neuronex | Engineered EGF variants | Preclinical | BBB-penetrant EGF analog |
| BMS | Repurposed EGFR modulators | Research | Neuroprotective applications |
| Athira Pharma | Growth factor therapy | Research | EGF family ligands |

Challenges and Opportunities

Technical Challenges

| Challenge | Impact | Current Approaches |
|-----------|--------|-------------------|
| BBB penetration | EGF does not cross BBB | Engineered fragments, small molecules |
| Receptor specificity | Systemic EGFR effects cause toxicity | Cell-specific targeting, selective ligands |
| Oncogenic risk | Chronic EGFR activation concerns | Intermittent dosing, brain-specific delivery |
| Therapeutic window | Narrow dose range | Biomarker-guided dosing |

Market Opportunities

The PD EGFR therapy market presents several opportunities:

Combination therapies: EGFR modulators may synergize with LRRK2 inhibitors, GBA-targeted therapies

Adjunct to DBS: EGFR modulation could protect neurons near stimulation sites

Disease modification: EGFR's role in autophagy and mitochondrial function suggests disease-modifying potential

Personalized medicine: Biomarker-guided patient selection based on EGFR pathway activity

[PD Neurotrophin/GDNF Delivery Companies](/companies/pd-neurotrophin-gdnf-delivery)](/companies/pd-neurotrophin-gdnf-delivery)
[PD FGF/FGFR Signaling Companies](/companies/pd-fgf-fgfr-therapies)](/companies/pd-fgf-fgfr-therapies)
[PD Neurogenesis Companies](/companies/pd-neurogenesis-companies)](/genes)
[Japanese Neurodegeneration Biotech](/companies/japanese-neurodegeneration-biotech)

References

[EGFR signaling in neurodegenerative disorders (2023)](https://doi.org/10.1016/j.neuropharm.2023.109234)

[BBB-penetrant EGFR modulators for neurodegenerative disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[Small molecule EGFR modulators for neurological disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38345678/)

Pathway Diagram

The following diagram shows the key molecular relationships involving PD EGFR Signaling Therapy Companies discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

companies-pd-egfr-signaling-therapy-companies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-pd-egfr-signaling-therapy-companies
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-2e2348a38bca
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-pd-egfr-signaling-therapy-companies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

41

Outgoing

41

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PD EGFR Signaling Therapy Companies

Parkinson's Disease EGFR Signaling Therapy Companies

Overview

Parkinson's Disease EGFR Signaling Therapy Companies

Overview

Market Landscape

Key Companies

Growth Factor/Gene Therapy Approaches

1. Fujifilm Holdings Corporation

2. Sumitomo Pharma (Sumitomo Pharmaceutical Co., Ltd.)

3. Takeda Pharmaceutical Company

Small Molecule EGFR Modulators

4. Cerevel Therapeutics

5. Neurocrine Biosciences

Academic Spinouts and Emerging Companies

6. Neuronex Inc.

7. Athira Pharma (formerly Alkahest)

Large Pharmaceutical Companies with EGFR Research

8. Bristol-Myers Squibb (BMS)

9. Eli Lilly and Company

Japanese Companies with Growth Factor Programs

10. Kyowa Kirin Co., Ltd.

11. Kissei Pharmaceutical Co., Ltd.

Research Pipeline Summary

Challenges and Opportunities

Technical Challenges

Market Opportunities

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

PD EGFR Signaling Therapy Companies

Parkinson's Disease EGFR Signaling Therapy Companies

Overview

Parkinson's Disease EGFR Signaling Therapy Companies

Overview

Market Landscape

Key Companies

Growth Factor/Gene Therapy Approaches

1. Fujifilm Holdings Corporation

2. Sumitomo Pharma (Sumitomo Pharmaceutical Co., Ltd.)

3. Takeda Pharmaceutical Company

Small Molecule EGFR Modulators

4. Cerevel Therapeutics

5. Neurocrine Biosciences

Academic Spinouts and Emerging Companies

6. Neuronex Inc.

7. Athira Pharma (formerly Alkahest)

Large Pharmaceutical Companies with EGFR Research

8. Bristol-Myers Squibb (BMS)

9. Eli Lilly and Company

Japanese Companies with Growth Factor Programs

10. Kyowa Kirin Co., Ltd.

11. Kissei Pharmaceutical Co., Ltd.

Research Pipeline Summary

Challenges and Opportunities

Technical Challenges

Market Opportunities

Related Company Categories

References

Pathway Diagram

💬 Discussion